Development of effective tumor immunotherapy using a novel dendritic cell-targeting Toll-like receptor ligand.
De Silva NH, Akazawa T, Wijewardana V, Inoue N, Oyamada M, Ohta A, Tachibana Y, Wijesekera DPH, Kuwamura M, Nishizawa Y, Itoh K, Izawa T, Hatoya S, Hasegawa T, Yamate J, Inaba T, Sugiura K.
De Silva NH, et al. Among authors: oyamada m.
PLoS One. 2017 Nov 30;12(11):e0188738. doi: 10.1371/journal.pone.0188738. eCollection 2017.
PLoS One. 2017.
PMID: 29190690
Free PMC article.